Tempus AI

Tempus AI EBITDA Margin

The EBITDA Margin of Tempus AI (TEM) as of Nov 19, 2026 is -18.60 %. In the previous year, EBITDA Margin was -97.90 % — a change of -81.00% (higher).

EBITDA Margin

-18.60 %

YoY

-81.00%

Last updated:

EBITDA Margin of Tempus AI is 2025 -18.60 % . EBITDA Margin of Tempus AI was 2024 -97.90 % . It decreases by -81.00% higher compared to the previous year.

The Tempus AI EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2019
-185.70 USD
Jan 1, 2020
-99.77 USD
Jan 1, 2021
-92.09 USD
Jan 1, 2022
-80.13 USD
Jan 1, 2023
-35.31 USD
Jan 1, 2024
-97.90 USD
Jan 1, 2025
-18.60 USD
The Tempus AI EBITDA Margin history
YEAREBITDA MarginYoY
-18.60 %-81.00%
-97.90 %+177.30%
-35.31 %-55.94%
-80.13 %-12.99%
-92.09 %-7.70%
-99.77 %-46.27%
-185.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

EBITDA Margin of Tempus AI is -18.60 % in 2025.

EBITDA Margin of Tempus AI changed from -97.90 % to -18.60 %, representing a -81.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Tempus AI since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tempus AI

All Key Metrics — Tempus AI